Human FCRL5/FCRL3 PE-conjugated Antibody

Monoclonal Mouse IgG_{2B} Clone # 307307

Catalog Number: FAB20871P

100 TESTS

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human FCRL5/FCRL3 in direct ELISAs. In direct ELISAs, 100% cross-reactivity with recombinant human (rh) FCRL3 is observed and no cross-reactivity with rhFCRL1, 2, or 4 is observed.
Source	Monoclonal Mouse IgG_{2B} Clone # 307307
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	Mouse myeloma cell line NS0-derived recombinant human FCRL5/FCRL3 Gln16-Arg844 Accession # AAI01067
Conjugate	Phycoerythrin Excitation Wavelength: 488 nm Emission Wavelength: 565-605 nm
Formulation	Supplied in a saline solution containing BSA and Sodium Azide. See Certificate of Analysis for details. *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: *Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.*

	Recommended Concentration	Sample
Flow Cytometry	10 µL/10^6 cells	See Below

DATA

Flow Cytometry



Detection of FCRL5/FCRL3 in $CD19^+$ Human Lymphocytes by Flow Cytometry. $CD19^+$ human lymphocytes were stained with Mouse Anti-Human FCRL5/FCRL3 PE-conjugated Monoclonal Antibody (Catalog # FAB20871P, filled histogram) or isotype control antibody (Catalog # IC0041P, open histogram). View our protocol for Staining Membrane-associated Proteins.

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	**Protect from light. Do not freeze.** ● 12 months from date of receipt, 2 to 8 °C as supplied.

bio-techne
bio-techne.com
Global info@bio-techne.com techsupport@bio-techne.com
North America TEL 800 343 7475 Europe | Middle East | Africa TEL +44 (0)1235 529449
China info.cn@bio-techne.com TEL +86 (21) 52380373
Rest of World bio-techne.com/find-us/distributors TEL +1 612 379 2956

Human FCRL5/FCRL3 PE-conjugated Antibody

Monoclonal Mouse IgG_{2B} Clone # 307307

Catalog Number: FAB20871P

100 TESTS

BACKGROUND

Fc Receptor-Like 5 (FCRL5), also known as FcRH5, IRTA2, and CD307, is a 120 kDa protein with sequence homology to classical Fc receptors. The type 1 transmembrane FCRL proteins contain from three to nine immunoglobulin-like domains. They are differentially expressed within the B cell lineage and can either promote or inhibit B cell proliferation and activation (1, 2). According to R&D Systems testing, FCRL5 binds to purified human IgG with high affinity. Mature human FCRL5 consists of a 836 amino acid (aa) extracellular domain (ECD) with nine Ig-like domains, a 21 aa transmembrane segment, and a 105 aa cytoplasmic domain with one Immunotyrosine Activation Motif (ITAM) and two Immunotyrosine Inhibitory Motifs (ITIMs) (1, 3). Mouse FCRL5 contains only five Ig-like domains in its ECD. It shares 49% aa sequence identity with human FCRL5 within common regions. Alternate splicing of human FCRL5 generates isoforms that consist of approximately the first one, six, or eight Ig-like domains (3, 4). FCRL5 expression is restricted to mature B lineage cells in lymphoid tissues and blood (3, 5-7). Its ligation inhibits signaling through the B cell antigen receptor (8). Epstein-Barr virus transformation of B cells induces the up-regulation of surface FCRL5 by a direct effect of its EBNA2 protein on FCRL5 gene transcription (9). The FCRL5 gene maps to the 1q21 chromosomal locus, a common site of rearrangements in B cell malignancies, and the FCRL5 protein is preferentially expressed in cell lines with 1q21 abnormalities (3). FCRL5 is up-regulated on tumor cells in some types of B cell malignancies (6, 10-12). In addition, soluble FCRL5 is elevated in the serum of many B cell leukemia patients (11, 13).

References:

1. Davis, R.S. (2007) Annu. Rev. Immunol. **25**:525.
2. Maltais, L.J. *et al.* (2006) Nat. Immunol. **7**:431.
3. Hatzivassiliou, G. *et al.* (2001) Immunity **14**:277.
4. SwissProt # Q96RD9.
5. Miller, I. *et al.* (2002) Blood **99**:2662.
6. Polson, A.G. *et al.* (2006) Int. Immunol. **18**:1363.
7. Vidal-Laliena, M. *et al.* (2005) Cell. Immunol. **236**:6.
8. Haga, C.L. *et al.* (2007) Proc. Natl. Acad. Sci. **104**:9770.
9. Mohan, J. *et al.* (2006) Blood **107**:4433.
10. Ise, T. *et al.* (2005) Clin. Cancer Res. **11**:87.
11. Ise, T. *et al.* (2007) Leukemia **21**:169.
12. Kazemi, T. *et al.* (2009) Cancer Immunol. Immunother. **58**:989.
13. Ise, T. *et al.* (2006) Clin. Chem. Lab. Med. **44**:594.

bio-techne
bio-techne.com
Global info@bio-techne.com techsupport@bio-techne.com
North America TEL 800 343 7475 Europe | Middle East | Africa TEL +44 (0)1235 529449
China info.cn@bio-techne.com TEL +86 (21) 52380373
Rest of World bio-techne.com/find-us/distributors TEL +1 612 379 2956